Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business share repurchase

Protagonist Therapeutics $300 Million Share Repurchase

Analysis based on 8 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026

Sentiment
40
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement signals confidence in Protagonist's financial strength and future cash flows, likely supporting its stock price. The repurchase program, funded by strong cash reserves and expected milestone payments, may enhance shareholder value and positively influence investor sentiment.

Biopharmaceuticals

On September 8, 2026, AnBogen Therapeutics announced that its Board of Directors authorized a share repurchase program of up to $300 million of its outstanding common stock. The company plans to fund the repurchases using its cash, cash equivalents, and marketable securities, as well as royalties and payments from its collaboration agreements with Takeda Pharmaceutical Company (related to MIMRYLO/rusfertide) and Johnson & Johnson (related to ICOTYDE/icotrokinra). As of June 30, 2026, Protagonist held $849.5 million in cash and marketable securities, excluding a $200 million opt-out payment and a $75 million milestone payment earned in August 2026 under the Takeda agreement, which are expected to be received in Q4 2026. The repurchase program is flexible and may be modified, suspended, or discontinued at any time. Protagonist is a biopharmaceutical company with two FDA-approved medicines, ICOTYDE and MIMRYLO, developed in partnership with Johnson & Johnson and Takeda.

100 AnBogen Therapeutics authorized share repurchase
priv
Protagonist is the company authorizing the $300 million share repurchase, funded by its cash and collaboration payments. This action signals financial strength and commitment to returning capital to shareholders, likely positively impacting its stock.
Importance 100.0 Sentiment 60.0
stock
Takeda is a collaboration partner whose royalty and milestone payments, including a $200 million opt-out and $75 million milestone, help fund the repurchase. This reflects ongoing successful partnership and financial inflows to Protagonist.
Importance 40.0 Sentiment 20.0
stock
Johnson & Johnson is a collaboration partner for ICOTYDE, and its royalty payments contribute to funding the repurchase. The event underscores the commercial value of the partnership.
Importance 30.0 Sentiment 10.0
subs
Johnson & Johnson — Janssen Pharmaceuticals, a Johnson & Johnson company, is the licensee of ICOTYDE. Its commercialization efforts generate royalties that support Protagonist's cash flow, indirectly enabling the repurchase.
Importance 10.0 Sentiment 5.0
govactor
The SEC is the regulatory body overseeing Protagonist's filings and the repurchase program's compliance. No direct impact on the SEC from this event.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.